We are live on ! Find out more
BLRX

BioLineRX
BLRX

23 hedge funds and large institutions have $13.6M invested in BioLineRX in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

10% more funds holding

Funds holding: 21 → 23 (+2)

20% less capital invested

Capital invested by funds: $17M → $13.6M (-$3.38M)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MC
Menta Capital
California
+$58.1K
2
LTFS
Ladenburg Thalmann Financial Services
Florida
+$48.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$31.5K
4
Creative Planning
Creative Planning
Kansas
+$31.5K
5
SM
Senvest Management
New York
+$28.2K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$480K
2
Deutsche Bank
Deutsche Bank
Germany
-$388K
3
Morgan Stanley
Morgan Stanley
New York
-$101K
4
CCB
Cutter & Co Brokerage
Missouri
-$19K
5
Jane Street
Jane Street
New York
-$8.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$4.68M +$28.2K +34 +0.6%
BC
2
Broadfin Capital
New York
$4.55M – – –
O
3
OrbiMed
New York
$1.35M – – –
Millennium Management
4
Millennium Management
New York
$780K – – –
Morgan Stanley
5
Morgan Stanley
New York
$594K -$101K -122 -14%
Alyeska Investment Group
6
Alyeska Investment Group
Illinois
$578K -$480K -578 -44%
OM
7
Opaleye Management
Massachusetts
$325K – – –
Deutsche Bank
8
Deutsche Bank
Germany
$316K -$388K -468 -54%
MC
9
Menta Capital
California
$115K +$58.1K +70 +90%
BCA
10
Benchmark Capital Advisors
New York
$61K – – –
NFG
11
Next Financial Group
Texas
$48K – – –
LTFS
12
Ladenburg Thalmann Financial Services
Florida
$46K +$48.1K +58 New
Commonwealth Equity Services
13
Commonwealth Equity Services
Massachusetts
$30K +$31.5K +38 New
Creative Planning
14
Creative Planning
Kansas
$30K +$31.5K +38 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$23K -$2.49K -3 -9%
AL
16
Airain Ltd
Guernsey
$19K -$7.47K -9 -27%
Jane Street
17
Jane Street
New York
$16K -$8.3K -10 -33%
PNC Financial Services Group
18
PNC Financial Services Group
Pennsylvania
$13K – – –
UBS Group
19
UBS Group
Switzerland
$11K +$6.64K +8 +133%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$4K – – –
TRCT
21
Tower Research Capital (TRC)
New York
$2K +$2.49K +3 New
KF
22
Krilogy Financial
Missouri
$1K – – –
Wells Fargo
23
Wells Fargo
California
$1K – – –
NCCM
24
Nine Chapters Capital Management
New Jersey
– -$92K -100 Closed
CCB
25
Cutter & Co Brokerage
Missouri
– -$19K -21 Closed

BLRX Hedge Fund Activity: Q4 2015 in Review

23 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2015, worth a combined $13.6M — down 20% from $17M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BLRX positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Menta Capital, adding an estimated $58.1K. The largest seller was Alyeska Investment Group, cutting an estimated $480K.

  • 23 institutional investors held BioLineRX (BLRX) as of Q4 2015, up from 21 in Q3 2015.
  • Funds reported $13.6M of BioLineRX stock for Q4 2015, down 20% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q4 2015 and 2 closed out, a net change of +2 holders.
  • The largest BioLineRX buyer in Q4 2015 was Menta Capital, an estimated $58.1K added.
  • The largest BioLineRX seller in Q4 2015 was Alyeska Investment Group, an estimated $480K sold.

Based on aggregated 13F filings for Q4 2015.